LSKL, Inhibitor of Thrombospondin TSP-1 2TFA NEW
| Price | $52 | $81 | $148 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | Purity: ≥98% |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA |
| Description | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β . |
| Animal Research | Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy. |
| In vivo | Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 27.5 mg/mL (40.05 mM) |
| Keywords | LSKL, Inhibitor of Thrombospondin TSP1 acetate | LSKL, Inhibitor of Thrombospondin TSP 1 acetate | LSKL, Inhibitor of Thrombospondin TSP-1 Acetate |
| Inhibitors Related | Monocrotaline | SB-431542 | DMH-1 | RepSox | Chromenone 1 | BMP signaling agonist sb4 | Pirfenidone | A 83-01 | Galunisertib | Alantolactone |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $38.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-07 | |
| $0.00/5Kg |
VIP1Y
|
SHANGHAI GEM CHEMICAL INDUSTRY CO.,LTD.
|
2024-12-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY